Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
In PLoS ONE, 2008
... Antibodies to p-STAT3, STAT3, p-ERK1/2, ERK1/2, p-EGFR, p-PDGFR-beta, PDGFR-beta, p-p65NF-kappaB, p65NF-kappaB were purchased from Cell Signaling Technology (Danvers, MA) ... Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
In British Journal of Cancer, 2001
... cyclin A, cdk-2, cdk-4, cdk-6, p27, Bax, Bad, Bcl-xL, Mcl-1, survivin, ERK1/2, VEGFR-2, phospho-VEGFR-2 Tyr951, phospho-PDGFR-β Tyr1021, and α-tubulin were from Santa Cruz Biotechnology Inc ...
Endometrial stem/progenitor cells: the first 10 years.
Australia. In Hum Reprod Update, Dec 2015
Specific markers for their enrichment have been identified, CD146(+)PDGFRβ(+) (platelet-derived growth factor receptor beta) and SUSD2(+) (sushi domain containing-2), which detected their perivascular location and likely pericyte identity in endometrial basalis and functionalis vessels.
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Ioánnina, Greece. In Trends Endocrinol Metab, Nov 2015
For example, inhibition of Abelson tyrosine kinase (c-Abl) results in β cell survival and enhanced insulin secretion, while platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) inhibition leads to improvement in insulin sensitivity.
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Los Angeles, United States. In Lancet Oncol, Jun 2015
We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of fibroblast growth factor receptors, VEGF receptors, PDGFR-β, and c-KIT, as second-line therapy both in patients with FGFR2-mutated (FGFR2(mut)) endometrial cancer and in those with FGFR2-non-mutated (FGFR2(non-mut)) endometrial cancer.
Endophilin marks and controls a clathrin-independent endocytic pathway.
Cambridge, United Kingdom. In Nature, Feb 2015
This pathway mediates the ligand-triggered uptake of several G-protein-coupled receptors such as α2a- and β1-adrenergic, dopaminergic D3 and D4 receptors and muscarinic acetylcholine receptor 4, the receptor tyrosine kinases EGFR, HGFR, VEGFR, PDGFR, NGFR and IGF1R, as well as interleukin-2 receptor.
Overview of fundamental study of pazopanib in cancer.
Tianjin, China. In Thorac Cancer, 2014
Through the exploration of inhibitors of vascular endothelial growth factor receptor (VEGFR)-2, deemed as the major angiogenesis pathway, pazopanib was found as a small molecular pan-VEGFR and pan-platelet-derived growth factor receptor (PDGFR) inhibitor, with suitable pharmacodynamic and pharmacokinetic parameters to be an oral drug.